Neurocrine Biosciences, Inc. (NBIX) analyst actions
NBIX analyst actions moved a median of +1.03% by the close. Rating and price-target actions on NBIX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NBIX overview →
11 measured NBIX analyst action events.
| Middle 50% of NBIX analyst action reactions | +0.13% to +1.29% |
|---|---|
| Median reaction (to close) | +1.03% |
| Measured reactions | 11 |
Half of the 11 NBIX analyst action events with a measured close landed between +0.13% and +1.29%; 91% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist | Press release | -0.93% | +1.16% | |
| Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia | Press release | -0.17% | +3.05% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist | Press release | +0.61% | +1.74% | |
| Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia | Press release | +0.42% | +0.11% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist | Press release | +0.75% | +1.43% | |
| Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia | Press release | +0.08% | +0.14% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults | Press release | +0.77% | +1.03% | |
| Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults | Press release | -0.23% | +1.15% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults | Press release | -0.25% | +0.21% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults | Press release | -0.91% | -3.12% | |
| Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults | Press release | -0.43% | +0.07% |
More NBIX: earnings → · SEC filings → · NBIX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kadmon Holdings, Inc. (KDMN) | 628 | 0.00% | 46% |
| GTX (GTXI) | 623 | 0.00% | 45% |
| Viveve Medical, Inc. (VIVE) | 621 | -0.82% | 38% |
| CHINA BIOLOGIC PRODUCTS (CBPO) | 619 | -0.04% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.